ReviewEuropean respiratory review : an official journal of the European Respiratory Society2022
Management of
Review in European respiratory review : an official journal of the European Respiratory Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Anti-interferon-γ autoantibodies syndrome and opportunistic infections: systematic literature review.Frontiers in immunology · 2025Pooled it
- Reactive oxygen detoxification contributes toeLife · 2026Article
- Detection ofMicroorganisms · 2026Article
- Mycobacterial cell division arrest and smooth-to-rough envelope transition using CRISPRi-mediated genetic repression systems.FEBS open bio · 2026Article
- Eravacycline forMicrobiology spectrum · 2026Article
- Efficacies of Sequenced Monotherapies of Mycobacterium avium Lung Infection in Mouse.The Journal of infectious diseases · 2026Article
- ERS Congress 2025: highlights from the Respiratory Infections Assembly.ERJ open research · 2026Article
- Machine learning-based model assists in differentiating Mycobacterium avium Complex Pulmonary Disease from Pulmonary Tuberculosis: A Multicenter Study.Journal of imaging informatics in medicine · 2026Article
- Species Distribution and Antimicrobial Susceptibility Profiles of Non-Tuberculous Mycobacteria in Nanjing, Jiangsu Province, China: A Three-Year Retrospective Study.Infection and drug resistance · 2026Article
- Predictive Value of Nutritional Status in Sputum Culture Conversion Among Patients with Nontuberculous Mycobacterial Pulmonary Disease: A Retrospective Cohort Study.Infection and drug resistance · 2026Article
- BioluminescentFrontiers in cellular and infection microbiology · 2026Article
- Clinical outcomes and adverse events of nontuberculous mycobacterial lung disease treated at an Italian tertiary referral center.Scientific reports · 2025Observational
- A Multiplexed, Target-Based Phenotypic Screening Platform Using CRISPR Interference inACS infectious diseases · 2025Article
- Efficacies of sequenced monotherapies ofbioRxiv : the preprint server for biology · 2025Article
- Genomic characterisation of recurrent Mycobacterium avium isolates from chronically infected patients reveals patterns of within-host evolution.Genome medicine · 2025Article
- TheMicroorganisms · 2025Review
- Microbial Clearance of RefractoryPharmaceuticals (Basel, Switzerland) · 2025Article
- Finding the optimal regimen forBMJ open · 2025Article
- Reactive Oxygen Detoxification Contributes tobioRxiv : the preprint server for biology · 2025Article
- An Antibody-Recruiting Molecule Enhances Fcγ Receptor-Mediated Uptake and Killing of Mycobacterial Pathogens by Macrophages.ACS infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nontuberculous mycobacterial pulmonary disease (NTM-PD) remains a challenging condition to diagnose and treat effectively. Treatment of NTM-PD is prolonged, frequently associated with adverse effects and has variable success. In this review, we consider the factors influencing clinicians when treating NTM-PD and discuss outcomes from key studies on the pharmacological management of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.